Redeye provides a research update following the Q2 report recently published by Magle. The second quarter of 2024 for Magle was primarily marked by the merger and acquisitions of Amniotics and pK Chemicals. We believe that both of these are poised to generate long-term shareholder value for Magle. Furthermore, the company reported a slightly higher sales figure than expected, a 21% y/y growth, with an increase in revenue from its DSM products. We raise our fair value range (SEK30 – SEK70) with a new base case valuation of SEK50.